F2G's Olorofim Shows Promise in High-Risk Hematology Patients with Invasive Aspergillosis
核心洞察
F2G (搜索) presented sub-analysis data from a Phase IIb trial of olorofim at ESCMID Global 2026, showing global success rates of 32-36% in hematology patients with invasive aspergillosis.
The first-in-class oral orotomide antifungal targets dihydroorotate dehydrogenase and can be administered simultaneously with immunosuppressants in high-risk patients.
Olorofim has completed Phase III trials and received multiple FDA designations, though a complete response letter in June 2023 requires additional data before approval.
F2G (搜索) presented promising data for its investigational antifungal agent olorofim at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference in Munich, Germany. The sub-analysis focused on highly immunosuppressed hematology patients with invasive aspergillosis, a population facing significant mortality risks and limited treatment options.
Novel Mechanism Targets Critical Patient Population
Olorofim represents a first-in-class oral orotomide that targets and inhibits dihydroorotate dehydrogenase (DHODH), offering a novel mechanism of action against resistant Aspergillus species, resistant molds, and dimorphic fungi. The drug's unique profile allows it to be administered simultaneously with immunosuppressants, making it particularly valuable for patients with hematologic malignancies who require ongoing immunosuppressive therapy.
The presented data came from a sub-analysis of a Phase IIb trial that investigated olorofim in patients 16 years of age and older with invasive fungal infections caused by Aspergillus, Lomentospora prolificans, Scedosporium, Coccidioides, and other invasive fungi with limited treatment options. The sub-analysis specifically evaluated highly immunosuppressed patients with hematologic malignancies, including those with acute myelogenous leukemia, hematopoietic cell transplantation, and graft-versus-host disease.
Clinical Efficacy in High-Risk Populations
Patients were divided into two groups: those with hematologic malignancies without neutropenia (HM) and those with hematologic malignancies with neutropenia at baseline (NAB). Global success rates, defined as complete or partial response to olorofim, reached 34% for the HM group and 32% for the NAB group at Day 42. These rates improved to 34% and 36%, respectively, at Day 84, remaining consistent with global success rates observed in the broader Phase IIb study of invasive aspergillosis patients.
All-cause mortality rates at Day 42 were 27% for the HM group and 36% for the NAB group, increasing to 35% and 45%, respectively, at Day 84. While these mortality rates were higher than those observed in the overall Phase IIb study population, researchers attributed this to the severity of the underlying hematologic diseases in this patient subset.
Addressing Critical Unmet Medical Need
Invasive aspergillosis represents a severe fungal infection that primarily affects immunocompromised patients, with symptoms including fever, chest pain, cough, coughing up blood, and shortness of breath. The infection carries a particularly high mortality burden among patients with hematologic malignancies, with 40-50% mortality rates at 12 weeks. Currently available antifungals face significant limitations including toxicity, drug-drug interactions, and increasing rates of resistance.
The safety profile of olorofim was analyzed in the Phase IIb study and found to be well-tolerated with low discontinuation rates, supporting its potential utility in this vulnerable patient population.
Regulatory Progress and Future Outlook
Olorofim has received significant regulatory recognition, including orphan drug designation from both the US Food and Drug Administration (FDA) and European Medicines Association (EMA). The FDA has also granted qualified infectious disease product (QIDP) designation, breakthrough therapy designation, and priority review designation for numerous fungal species.
However, the regulatory path has encountered challenges. The FDA issued a complete response letter regarding olorofim's new drug application in June 2023, stating it could not approve the drug at that time and requesting additional data and analyses. F2G (搜索) is expected to submit a revised NDA to the FDA, though the exact timeline remains uncertain.
The company has recently completed a Phase III trial comparing olorofim's efficacy, safety, and tolerability to AmBisome (liposomal amphotericin B) in patients with invasive aspergillosis and limited treatment options. If successful, olorofim's entry into the antifungal market could provide diverse applications across a wide range of fungal infections, particularly addressing the lack of treatment options for patients with hematologic malignancies and invasive aspergillosis.